Issue 39, 2024, Issue in Progress
From the journal:

RSC Advances

Expression of concern: HDACI regulates the PI3K/Akt signaling pathway to reverse MCF-7/PTX resistance by inhibiting SET

Weipeng Zhang,ab   Xiaowei Zheng,a   Ti Meng,a   Haisheng You,a   Yalin Dong,a   Jianfeng Xing*c  and  Siying Chen*a  

* Corresponding authors

a Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, No. 277 of Yanta West Road, Xi'an, Shaanxi 710061, PR China
E-mail: ychen0326@163.com
Fax: +86-29-85323240
Tel: +86-29-85323243

b Department of Pharmacy, The Eighth Hospital of Xi'an, Xi'an, Shaanxi 710061, PR China

c School of Pharmacy, Xi'an Jiaotong University, No. 76 of Yanta West Road, Xi'an, Shaanxi 710061, PR China
E-mail: xajdxjf@mail.xjtu.edu.cn
Fax: +86-29-82655130
Tel: +86-29-82655130

Abstract

Expression of concern for ‘HDACI regulates the PI3K/Akt signaling pathway to reverse MCF-7/PTX resistance by inhibiting SET’ by Weipeng Zhang et al., RSC Adv., 2016, 6, 48072–48082, https://doi.org/10.1039/C6RA06423J

About
Cited by
Related
Download options Please wait...

Associated articles

Article information

DOI
https://doi.org/10.1039/D4RA90094D
Article type
Expression of Concern
Submitted
28 Aug 2024
Accepted
28 Aug 2024
First published
04 Sep 2024
This article is Open Access
Creative Commons BY license

RSC Adv., 2024,14, 28300-28300

Permissions

Request permissions

Expression of concern: HDACI regulates the PI3K/Akt signaling pathway to reverse MCF-7/PTX resistance by inhibiting SET

W. Zhang, X. Zheng, T. Meng, H. You, Y. Dong, J. Xing and S. Chen, RSC Adv., 2024, 14, 28300 DOI: 10.1039/D4RA90094D

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements